Topotecan combination chemotherapy in two new rodent models of retinoblastoma.
about
Use of preclinical models to improve treatment of retinoblastoma.Establishment of an Orthotopic Xenograft Mice Model of Retinoblastoma Suitable for Preclinical TestingTransgenic Models in Retinoblastoma ResearchEfficient photodynamic therapy on human retinoblastoma cell linesMultimodality imaging methods for assessing retinoblastoma orthotopic xenograft growth and developmentTopotecan Delivery to the Optic Nerve after Ophthalmic Artery ChemosurgerySchedule-Dependent Antiangiogenic and Cytotoxic Effects of Chemotherapy on Vascular Endothelial and Retinoblastoma CellsCarboplatin +/- topotecan ophthalmic artery chemosurgery for intraocular retinoblastoma.Topotecan and vincristine combination is effective against advanced bilateral intraocular retinoblastoma and has manageable toxicityOcular Salvage and Vision Preservation Using a Topotecan-Based Regimen for Advanced Intraocular RetinoblastomaSubconjunctival carboplatin and systemic topotecan treatment in preclinical models of retinoblastoma.Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration.Targeting the p53 pathway in retinoblastoma with subconjunctival Nutlin-3a.Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma.Novel miRNA-31 and miRNA-200a-Mediated Regulation of Retinoblastoma ProliferationIntravitreal Topotecan Inhibits Laser-induced Choroidal Neovascularization in a Rat Model.Targeting Survivin Enhances Chemosensitivity in Retinoblastoma Cells and Orthotopic Tumors.Cross-species genomic and epigenomic landscape of retinoblastoma.AAV-mediated local delivery of interferon-beta for the treatment of retinoblastoma in preclinical modelsChanges in retinoblastoma cell adhesion associated with optic nerve invasion.Intra-ophthalmic artery chemotherapy triggers vascular toxicity through endothelial cell inflammation and leukostasis.Models and discovery strategies for new therapies of retinoblastoma.Lessons from Retinoblastoma: Implications for Cancer, Development, Evolution, and Regenerative Medicine.Camptothecin induces apoptosis of human retinoblastoma cells via activation of FOXO1.Chemoreduction of Progressive Intraocular Retinoblastoma by Systemic Topotecan.Retinoblastoma cells activate the AKT pathway and are vulnerable to the PI3K/mTOR inhibitor NVP-BEZ235.Inactivation of the p53 pathway in retinoblastoma.The war on cancer: have we won the battle but lost the war?Animal models in retinoblastoma research.Childhood cancer and developmental biology a crucial partnership.Retinoblastoma, the visible CNS tumor: A review.Ocular topotecan pharmacokinetics following topical administration to rabbits for diffused anterior retinoblastoma.Update on intra-arterial chemotherapy for retinoblastoma
P2860
Q21144714-0EAE1090-D1BF-4511-B7C8-34C14BBC4ABDQ26750379-D8D15761-E045-4BB1-A7B0-B62F76E98DA4Q26750411-2EAD29E0-5F32-4CFE-B6C3-1E9C0DB8E0FBQ27324555-39A3DC89-C3F0-439C-8424-39E18FC047FFQ28539433-0B49147F-9F84-4A05-95D6-60D72AB8F6E0Q28550610-B4087478-2B30-4582-BB32-B255CB43B806Q28553176-64B47F7D-A3EF-499A-B2CA-576BB7DE3528Q31132958-F9525AA9-7DD7-4A7A-923A-E57BE2542F45Q33400825-E86C5E45-AFCD-441A-B7DA-6EE192947ED5Q33437979-929C319B-6685-44D7-B564-F886610517FAQ34398223-3C7D74A4-BCFD-4F14-BFAF-210D56C4D79DQ34458379-7C915D18-D850-49C9-A6D5-4A4C5CA9A397Q35050530-B42973EC-00BD-4BF1-A716-BC8A477D81E3Q35706804-57ACFD83-7CDD-4978-9040-34DBD97D2272Q35778751-C4DA1C01-D252-4176-8F84-590F4B961183Q35884935-833918B6-0B27-49CB-B270-7C8EBDDF3492Q35981061-977CDD71-16CF-4BF2-9D14-D5CF84AFB2F2Q37132228-461B059E-B068-4A2C-8B51-ED229F342071Q37301637-0E22E0F4-952E-4066-AC0C-9C49849A3263Q37451910-0F8E58B7-EAEA-45C5-8AF5-8BCDBA50CE28Q37716540-D89299BA-DEF3-40B0-BA77-88E5766081BCQ38083299-B419604C-A00D-43A4-9BDE-DB2FF29F8A81Q38938719-69047C66-566D-48D7-8EF9-422C693907E0Q39803115-03BD12B1-C319-42B7-B13D-1867DAB63BBCQ40114455-C6008D69-FEA3-4816-BAA0-89828D5D14B3Q40970798-CE89BE1C-4FFC-4293-9908-9CB3732F4AFFQ42152329-1E42053B-2F31-45C7-8540-79FC1F2191C5Q42419701-F75FB7EF-F8D0-4149-A24B-AA3F687EC3DBQ42600561-38648EFD-9749-4DD6-ADB5-C3927B04BAF6Q42917104-F2D2BAD5-EEB1-4397-AF81-7DF02B84DE64Q48288706-68BC451D-C936-4800-B64B-6618CA62002DQ54697731-C7587CD7-C69A-4013-870C-B50B15CD8AC2Q56882332-A32BA95E-6524-4F77-B7E4-A3AE1091087F
P2860
Topotecan combination chemotherapy in two new rodent models of retinoblastoma.
description
2005 nî lūn-bûn
@nan
2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Topotecan combination chemotherapy in two new rodent models of retinoblastoma.
@ast
Topotecan combination chemotherapy in two new rodent models of retinoblastoma.
@en
type
label
Topotecan combination chemotherapy in two new rodent models of retinoblastoma.
@ast
Topotecan combination chemotherapy in two new rodent models of retinoblastoma.
@en
prefLabel
Topotecan combination chemotherapy in two new rodent models of retinoblastoma.
@ast
Topotecan combination chemotherapy in two new rodent models of retinoblastoma.
@en
P2093
P1476
Topotecan combination chemotherapy in two new rodent models of retinoblastoma.
@en
P2093
Clinton Stewart
Jiakun Zhang
Jonathan K Gray
Mark Leggas
Mary Relling
Merrill Egorin
Michael A Dyer
Nikia A Laurie
P304
P356
10.1158/1078-0432.CCR-05-0849
P407
P577
2005-10-01T00:00:00Z